生物製剤アウトソーシング市場：製品タイプ、用途、供給元、サービスタイプ、エンドユーザー、治療領域別-2025-2030年世界予測

生物製剤アウトソーシング市場は、2023年に205億6,000万米ドルと評価され、2024年には228億7,000万米ドルに達すると予測され、CAGR 12.18％で成長し、2030年には459億8,000万米ドルに達すると予測されています。

生物製剤アウトソーシングは、生物学的製剤の製造・開発プロセスを専門の第三者サービスプロバイダーに外部委託することを含みます。その範囲には、細胞株開発、プロセス開発、分析特性評価、製剤化、生産などの活動が含まれます。この必要性は、タンパク質、抗体、遺伝子治療薬を含む生物学的製剤の複雑な性質から生じ、専門的な専門知識と設備が要求されます。アプリケーションは、製品開発の迅速化、社内設備への資本支出の削減、コアコンピタンスへのリソースの集中を目指す製薬会社やバイオテクノロジー企業に及んでいます。最終用途の範囲は、腫瘍学、自己免疫疾患、希少遺伝性疾患などの治療分野にまで及ぶ。生物製剤アウトソーシング市場に影響を与える主な成長要因としては、慢性疾患の増加、バイオテクノロジーの発展、生物学的製剤開発への投資拡大などが挙げられます。新興市場は、運用コストの低下とヘルスケアインフラの拡大により、潜在的なビジネスチャンスをもたらしています。このような機会を捉えるための推奨事項としては、現地のサービスプロバイダーとの戦略的提携や技術移転への関与が挙げられます。しかし、厳しい規制要件、知的財産の安全性に対する懸念、品質基準のばらつきといった課題も残っています。こうした要因は、特に規制の枠組みが成熟していない地域では、市場拡大の妨げとなる可能性があります。このような課題にもかかわらず、シングルユース技術、自動化、高度分析などの分野における技術革新は、生物製剤生産の効率性と拡張性を高める上で大きな可能性を秘めています。企業は、競争優位性を維持するために、費用対効果の高いバイオプロセス技術と個別化医療の開発に注力することができます。さらに、生物製剤の研究開発と製造における人工知能と機械学習の統合を含むデジタルトランスフォーメーションは、大きなブレークスルーをもたらす可能性があります。市場の特徴はダイナミックで競合情勢が激しいことであり、大規模な開発・製造受託機関（CDMO）がニッチなサービスプロバイダーを買収して能力と地域的リーチを拡大し、市場での地位を強化することで、統合が進む傾向にあります。

市場力学：急速に進化する生物製剤アウトソーシング市場の主要市場インサイトを公開

生物製剤アウトソーシング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 厳しい規制要件と生物製剤製造におけるコンプライアンス専門知識の必要性
  • 生物製剤製造のアウトソーシングを促進するコスト効率と時間短縮のメリット
  • 製薬会社による生物製剤パイプラインの拡大により、外部製造サポートが必要
  • アウトソーシング企業によるシングルユース技術と連続バイオプロセスの採用
• 市場抑制要因
  • 専門的な生物製剤の製造やプロセス開発に携わる熟練労働力の不足
  • 外部委託中の生物学的製剤の品質のばらつきは潜在的なリスクと負債につながる
• 市場機会
  • 手頃な価格の生物製剤製造ソリューションを求める中小バイオテクノロジー企業との提携機会
  • ニッチ治療領域における専門的な生物製剤開発サービスへのニーズの高まり
  • 生物製剤開発における製薬企業と研究開発受託機関の協力関係の高まり
• 市場の課題
  • 生物製剤アウトソーシング市場におけるサプライチェーンの混乱とロジスティクスの課題管理
  • 生物製剤アウトソーシングサービスにおける高い品質基準を維持しつつ、コスト効率を確保すること

ポーターの5つの力：生物製剤アウトソーシング市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、生物製剤アウトソーシング市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生物製剤アウトソーシング市場における外部からの影響の把握

外部マクロ環境要因は、生物製剤アウトソーシング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生物製剤アウトソーシング市場における競合情勢の把握

生物製剤アウトソーシング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生物製剤アウトソーシング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生物製剤アウトソーシング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生物製剤アウトソーシング市場における成功への道筋を描く

生物製剤アウトソーシング市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 厳しい規制要件と生物製剤製造におけるコンプライアンスの専門知識の必要性
    • コスト効率と時間短縮のメリットがバイオ医薬品製造のアウトソーシングを推進
    • 製薬会社によるバイオ医薬品パイプラインの拡大により外部製造サポートが必要に
    • アウトソーシング企業による使い捨て技術と連続バイオプロセスの採用
  • 抑制要因
    • 特殊な生物製剤の製造とプロセス開発のための熟練労働力が限られている
    • アウトソーシング中の生物学的製品の品質の変動は潜在的なリスクと責任につながる
  • 機会
    • 手頃な価格の生物製剤製造ソリューションを求める小規模バイオテクノロジー企業との提携機会
    • ニッチな治療領域における専門的な生物製剤開発サービスに対するニーズの高まり
    • バイオ医薬品開発における製薬会社と受託調査機関の連携の拡大
  • 課題
    • サプライチェーンの混乱と物流の課題への対応生物製剤アウトソーシング市場
    • 生物製剤アウトソーシングサービスにおいて高品質基準を維持しながらコスト効率を確保する
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 生物製剤アウトソーシング市場：製品タイプ別

• アンチセンス、RNAi、分子療法
• モノクローナル抗体
• その他の生物学的製剤
• 組み換えタンパク質
• ワクチン

第7章 生物製剤アウトソーシング市場：用途別

• 心血管疾患
• 免疫学
  • アレルギー疾患
  • 自己免疫疾患
• 感染症
  • 細菌感染症
  • ウイルス感染
• 神経学
• 腫瘍学
  • がんバイオマーカー研究
  • 個別化がん治療
• その他のアプリケーション

第8章 生物製剤アウトソーシング市場：ソース別

• 哺乳類
• 非哺乳類
  • 細菌
  • 昆虫細胞
  • 植物細胞
  • 酵母

第9章 生物製剤アウトソーシング市場：サービスタイプ別

• 分析と品質管理
• 臨床試験
• 充填および仕上げ作業
• プロセス開発
• 規制サービス

第10章 生物製剤アウトソーシング市場：エンドユーザー別

• バイオテクノロジー企業
• 契約調査機関（CRO）
• 製薬会社
• 調査機関

第11章 生物製剤アウトソーシング市場治療領域別

• がん
• 心血管疾患
• 感染症
• 炎症および免疫疾患
• 代謝障害
• 神経疾患

第12章 南北アメリカの生物製剤アウトソーシング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の生物製剤アウトソーシング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの生物製剤アウトソーシング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Biocon Limited
• 4. Boehringer Ingelheim GmbH
• 5. Catalent, Inc.
• 6. Charles River Laboratories International, Inc.
• 7. Covance Inc.
• 8. Eli Lilly and Company
• 9. Fujifilm Diosynth Biotechnologies
• 10. Genentech, Inc.
• 11. Icon plc
• 12. Lonza Group AG
• 13. Merck KGaA
• 14. Novartis AG
• 15. Parexel International Corporation
• 16. Pfizer Inc.
• 17. Samsung Biologics Co., Ltd.
• 18. Sandoz International GmbH
• 19. Thermo Fisher Scientific Inc.
• 20. WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. BIOLOGICS OUTSOURCING MARKET RESEARCH PROCESS
• FIGURE 2. BIOLOGICS OUTSOURCING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOLOGICS OUTSOURCING MARKET DYNAMICS
• TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANTISENSE, RNAI, AND MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLERGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER BIOMARKER STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PERSONALIZED CANCER TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL AND FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFLAMMATORY AND IMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 90. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 92. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 93. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 134. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 138. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 142. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 144. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 145. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 148. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 152. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 153. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 154. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 155. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 156. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 162. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 164. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 165. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 166. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 172. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 174. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 175. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 182. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 184. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 185. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 194. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 195. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 196. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 202. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 203. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 204. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 205. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 214. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 222. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 223. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 224. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 225. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 232. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 234. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 235. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 242. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 243. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 244. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 245. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 246. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 263. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 265. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 266. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 267. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 268. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 273. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 274. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 275. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 276. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 277. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 283. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 284. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 285. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 286. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 287. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 288. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 291. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 292. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 293. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 294. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 295. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 296. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 297. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 298. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 301. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 302. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 303. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 304. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 305. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 306. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 307. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 308. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 311. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 312. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 313. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 314. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 315. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 316. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 317. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 318. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 319. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 320. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 321. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 322. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 323. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 324. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 325. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 326. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 327. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 328. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 330. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 331. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
• TABLE 332. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 333. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 334. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 335. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
• TABLE 336. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 337. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 338. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 339. NIGERIA BIOLOGICS

The Biologics Outsourcing Market was valued at USD 20.56 billion in 2023, expected to reach USD 22.87 billion in 2024, and is projected to grow at a CAGR of 12.18%, to USD 45.98 billion by 2030.

Biologics outsourcing involves externalizing the production and development processes of biologic drugs to specialized third-party service providers. The scope includes activities such as cell line development, process development, analytical characterization, formulation, and production. This necessity arises from the complex nature of biologic drugs, which include proteins, antibodies, and gene therapies, demanding specialized expertise and facilities. Applications span across pharmaceuticals and biotechnology companies aiming to expedite product development, reduce capital expenditure on in-house facilities, and focus resources on core competencies. The end-use scope extends to therapeutic areas including oncology, autoimmune diseases, and rare genetic disorders. Key growth factors influencing the biologics outsourcing market include the increasing prevalence of chronic diseases, advancements in biotechnology, and growing investment in biologic drug development. Emerging markets offer potential opportunities, driven by lower operational costs and expanding healthcare infrastructures. Recommendations for capturing these opportunities include forming strategic alliances with local service providers and engaging in technology transfers. However, challenges persist, such as stringent regulatory requirements, concerns over intellectual property security, and variability in quality standards. These factors can hinder market expansion, particularly across regions with less mature regulatory frameworks. Despite these challenges, innovation in areas such as single-use technologies, automation, and advanced analytics holds significant promise for enhancing efficiency and scalability in biologics production. Companies could focus on the development of cost-effective bioprocessing technologies and personalized medicine to maintain competitive advantage. Furthermore, digital transformation, including the integration of artificial intelligence and machine learning in biologic R&D and manufacturing, can lead to significant breakthroughs. The market is characterized by a dynamic and competitive landscape, with a trend towards consolidation, as larger contract development and manufacturing organizations (CDMOs) acquire niche service providers to expand capabilities and geographical reach, thereby strengthening their market position.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Outsourcing Market

The Biologics Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Stringent regulatory requirements and the need for compliance expertise in biologics production
  • Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
  • Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
  • Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
• Market Restraints
  • Limited availability of skilled workforce for specialized biologics manufacturing and process development
  • Variability in biological product quality during outsourcing leading to potential risks and liabilities
• Market Opportunities
  • Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
  • Growing need for specialized biologics development services in niche therapeutic areas
  • Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
• Market Challenges
  • Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
  • Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Outsourcing Market

A detailed market share analysis in the Biologics Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Outsourcing Market

A strategic analysis of the Biologics Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Outsourcing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biocon Limited, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Covance Inc., Eli Lilly and Company, Fujifilm Diosynth Biotechnologies, Genentech, Inc., Icon plc, Lonza Group AG, Merck KGaA, Novartis AG, Parexel International Corporation, Pfizer Inc., Samsung Biologics Co., Ltd., Sandoz International GmbH, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Antisense, RNAi, And Molecular Therapy, Monoclonal Antibodies, Other Biologics, Recombinant Proteins, and Vaccines.
• Based on Application, market is studied across Cardiovascular Diseases, Immunology, Infectious Diseases, Neurology, Oncology, and Other Applications. The Immunology is further studied across Allergic Disorders and Autoimmune Diseases. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Cancer Biomarker Studies and Personalized Cancer Treatments.
• Based on Source, market is studied across Mammalian and Non-Mammalian. The Non-Mammalian is further studied across Bacteria, Insect Cells, Plant Cells, and Yeast.
• Based on Service Type, market is studied across Analytical And Quality Control, Clinical Trials, Fill And Finish Operations, Process Development, and Regulatory Services.
• Based on End User, market is studied across Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical Companies, and Research Institutes.
• Based on Therapeutic Area, market is studied across Cancer, Cardiovascular Diseases, Infectious Diseases, Inflammatory And Immune Disorders, Metabolic Disorders, and Neurological Conditions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Stringent regulatory requirements and the need for compliance expertise in biologics production
    • 5.1.1.2. Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
    • 5.1.1.3. Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
    • 5.1.1.4. Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of skilled workforce for specialized biologics manufacturing and process development
    • 5.1.2.2. Variability in biological product quality during outsourcing leading to potential risks and liabilities
  • 5.1.3. Opportunities
    • 5.1.3.1. Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
    • 5.1.3.2. Growing need for specialized biologics development services in niche therapeutic areas
    • 5.1.3.3. Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
  • 5.1.4. Challenges
    • 5.1.4.1. Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
    • 5.1.4.2. Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biologics Outsourcing Market, by Product Type

• 6.1. Introduction
• 6.2. Antisense, RNAi, And Molecular Therapy
• 6.3. Monoclonal Antibodies
• 6.4. Other Biologics
• 6.5. Recombinant Proteins
• 6.6. Vaccines

7. Biologics Outsourcing Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular Diseases
• 7.3. Immunology
  • 7.3.1. Allergic Disorders
  • 7.3.2. Autoimmune Diseases
• 7.4. Infectious Diseases
  • 7.4.1. Bacterial Infections
  • 7.4.2. Viral Infections
• 7.5. Neurology
• 7.6. Oncology
  • 7.6.1. Cancer Biomarker Studies
  • 7.6.2. Personalized Cancer Treatments
• 7.7. Other Applications

8. Biologics Outsourcing Market, by Source

• 8.1. Introduction
• 8.2. Mammalian
• 8.3. Non-Mammalian
  • 8.3.1. Bacteria
  • 8.3.2. Insect Cells
  • 8.3.3. Plant Cells
  • 8.3.4. Yeast

9. Biologics Outsourcing Market, by Service Type

• 9.1. Introduction
• 9.2. Analytical And Quality Control
• 9.3. Clinical Trials
• 9.4. Fill And Finish Operations
• 9.5. Process Development
• 9.6. Regulatory Services

10. Biologics Outsourcing Market, by End User

• 10.1. Introduction
• 10.2. Biotechnology Companies
• 10.3. Contract Research Organizations (CROs)
• 10.4. Pharmaceutical Companies
• 10.5. Research Institutes

11. Biologics Outsourcing Market, by Therapeutic Area

• 11.1. Introduction
• 11.2. Cancer
• 11.3. Cardiovascular Diseases
• 11.4. Infectious Diseases
• 11.5. Inflammatory And Immune Disorders
• 11.6. Metabolic Disorders
• 11.7. Neurological Conditions

12. Americas Biologics Outsourcing Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Biologics Outsourcing Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Outsourcing Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Biocon Limited
• 4. Boehringer Ingelheim GmbH
• 5. Catalent, Inc.
• 6. Charles River Laboratories International, Inc.
• 7. Covance Inc.
• 8. Eli Lilly and Company
• 9. Fujifilm Diosynth Biotechnologies
• 10. Genentech, Inc.
• 11. Icon plc
• 12. Lonza Group AG
• 13. Merck KGaA
• 14. Novartis AG
• 15. Parexel International Corporation
• 16. Pfizer Inc.
• 17. Samsung Biologics Co., Ltd.
• 18. Sandoz International GmbH
• 19. Thermo Fisher Scientific Inc.
• 20. WuXi AppTec Co., Ltd.